Please ensure Javascript is enabled for purposes of website accessibility

Thermo Fisher Scientific to Spend $11.5 Billion Upgrading Its DNA Testing Game

By Cory Renauer - Mar 3, 2020 at 11:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The world's leading provider of scientific tools will buy QIAGEN and its growing menu of molecular diagnostic products.

On Tuesday, Thermo Fisher Scientific (TMO -2.24%) announced its intent to acquire a leading global provider of testing technology, QIAGEN N.V. (QGEN -4.21%) for $11.5 billion. That deal valuation includes $1.4 billion of the Netherlands-based company's outstanding debt.

A major COVID-19 player overnight 

It's hard to imagine a well-run company like Thermo Fisher authorizing an 11-figure acquisition solely to chase the latest virus outbreak. That said, recent progress made by the molecular diagnostics specialist in developing a test for the novel coronavirus SARS-CoV-2 probably nudged Thermo Fisher's decision along.

DNA model

Image source: Getty Images.

Since January, Qiagen has been providing instruments and test kits used to detect the coronavirus that causes COVID-19. In late February, Qiagen announced initial shipments of test kits that can rapidly differentiate between the coronavirus responsible for COVID-19 infections and 21 other pathogens that present similar symptoms. 

A long-term gambit

Test kits for SARS-CoV-2 could be big sellers in the year ahead, but Thermo Fisher's bet on Qiagen is part of a much larger strategy. New therapies for cancer and other diseases are increasingly being tailored to match the specific genetic profiles of patients and their cancers. This purchase will immediately embed Thermo Fisher even more firmly in the spaces between drug developers and healthcare providers.

For example, Qiagen and Amgen (AMGN -0.57%) recently announced a collaboration to develop a companion diagnostic that will be used to gauge which cancer patients are eligible to receive Amgen's candidate treatment AMG 510 if that drug earns approval. The diagnostics industry is hyper-competitive, but having the only FDA-approved test that can determine which patients should be given a popular treatment could provide it with a significant and relatively reliable source of revenue. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$43.96 (-4.21%) $-1.93
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$542.17 (-2.24%) $-12.43
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$243.96 (-0.57%) $-1.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.